{"id":"NCT00319046","sponsor":"Actelion","briefTitle":"Clinical Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Miglustat in Patients With Stable Type 1 Gaucher Disease","officialTitle":"Open-label, Non Comparative, Multi-center Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Oral Miglustat as a Maintenance Therapy After a Switch From Enzyme Replacement Therapy in Adult Patients With Stable Type 1 Gaucher Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02-01","primaryCompletion":"2010-06-01","completion":"2010-07-01","firstPosted":"2006-04-27","resultsPosted":"2012-05-23","lastUpdate":"2025-02-04"},"enrollment":42,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Gaucher Disease Type 1"],"interventions":[{"type":"DRUG","name":"Miglustat","otherNames":["Zavesca"]}],"arms":[{"label":"Open-label miglustat","type":"EXPERIMENTAL"}],"summary":"Although miglustat has been approved as a treatment for mild to moderate type 1 Gaucher disease in patients who are unsuitable for enzyme replacement therapy (ERT), more data are required to establish the long term efficacy, safety and tolerability of miglustat in maintaining diseases stability after a switch from ERT.","primaryOutcome":{"measure":"Liver Volume at Baseline and at End of Treatment","timeFrame":"Baseline and end of treatment (Month 24)","effectByArm":[{"arm":"Miglustat","deltaMin":1774.6,"sd":484.07}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["23270487"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":42},"commonTop":["DIARRHOEA","FLATULENCE","TREMOR","HEADACHE","PARAESTHESIA"]}}